Schedule

As the life sciences industry navigates a rapidly shifting regulatory landscape, legal counsel play a critical role in guiding organizations through complex compliance, enforcement, and policy developments. New FDA initiatives impacting health care providers (HCPs), AI-enabled technologies, clinical research transparency, and real-world evidence—coupled with heightened scrutiny from DOJ and OIG—are reshaping risk profiles across the sector and impacting hospitals, health systems, and providers with whom they interact.
This session will examine the key regulatory and compliance challenges confronting life science companies from a legal and compliance perspective. Panelists will analyze recent enforcement actions, discuss emerging trends, and explore how legal teams can proactively partner with compliance and business leaders to manage evolving risks. By the end of the session, participants will be able to:

• Assess the most significant regulatory trends impacting pharmaceutical, medical device, biotechnology, and other life science organizations
• Highlight new and pending FDA, OIG, and DOJ guidance to anticipate enforcement priorities and adjust risk mitigation strategies
• Identify best practices for legal departments to support innovation while maintaining strong compliance alignment
• Apply lessons from recent case studies to strengthen collaboration between legal, compliance, and operational stakeholders

• Update on staffing, operations, and budget
• Interagency collaboration and cooperation
• Enforcement priorities
• Remedies-Consequential damages
• Restrictive covenants
• Case law updates and predictions

• How existing compliance structures (HIPAA, Stark, Anti-Kickback, FDA oversight, corporate integrity agreements) can evolve to govern algorithmic decision-making tools. (For example, HIPAA (Privacy and Security)–Governs how patient health information is collected, stored, and shared. AI connection: Algorithms rely on massive datasets, sometimes repurposed in ways not anticipated when consent was obtained. Evolving focus: Ensuring algorithmic data use, secondary data analytics, and training datasets comply with HIPAA’s privacy and security safeguards. That includes questions like: Is de-identified data used properly for AI model training? Are automated outputs considered part of the designated record set? How do we secure AI vendors under Business Associate Agreements (BAAs)? Define the core pillars of AI compliance—transparency, accountability, fairness, auditability, and human oversight—and how each intersects with current health law obligations.
• How to operationalize AI governance programs, including risk-tiering models, documentation standards, validation protocols, and lifecycle monitoring
• Emerging enforcement trends and policy initiatives related to health care AI across the U.S. and EU (FDA, HHS/OCR, EU AI Act)
• Examples of how human eyes still need to review AI generated documents to ensure compliance while enabling innovation
• The ethical challenges posed by algorithmic bias and automation bias in AI-assisted clinical decision-making
• The legal risks associated with physician reliance on AI-generated diagnostic or treatment recommendations
• Practical takeaways: Templates, governance checklists, and defensible documentation strategies for legal and compliance teams

• Breaking down the OIG Compliance Guidance for Medicare Advantage Industry Segment
• Hot issues: RADV, AI, and prior authorizations
• What’s new for plans
• Operational impacts for providers
• Practical tips for aligning compliance programs with the new expectations

Through executive orders, new priorities, and policy changes, the second Trump administration has given DOJ a broad mandate for health care-related enforcement. This panel will feature a dynamic exchange among False Claims Act experts as they unpack the Administration’s key moves and assess the implications for health care providers and potential ways to respond. Topics will include:

• The changing enforcement landscape affecting the health care industry
• Key enforcement cases during the second Trump Administration
• Executive Orders impacting enforcement
• DOJ’s continued emphasis on leniency programs and whistleblowers
• How the Trump Administration is responding to the role of private equity in the health care industry
• Other emerging enforcement trends

This session will examine the legal, regulatory, and operational complexities involved in developing and opening new and unique health care facilities. Drawing on two real world case studies, the presentation will highlight the strategic role of counsel from initial planning through operational launch, with a focus on anticipating risk, managing uncertainty, and aligning legal strategy with evolving business objectives.

• Practical, lawyer focused takeaways for navigating federal, state, and local regulatory requirements
• Common regulatory notice, approval, and change of ownership schemes
• Integration challenges, such as the governance challenges encountered with strategic partnerships
• How to incorporate flexibility into legal and operational structures
• How to adjust plans to accommodate evolving stakeholder expectations

This session will explore the intersection of private equity investment, health care regulatory frameworks, and state and federal false claims act exposure. The presenters will discuss the theories seeking to implicate investors for portfolio company misconduct, analyze the evolving enforcement posture, and provide practical guidance for managing compliance risk. We will discuss:

• How private equity ownership structures can intersect with state and federal false claims acts and fraud-and-abuse laws
• Potential red flags in investment transactions and operations that could expose investors or portfolio companies to state and federal false claims act liability and areas that government and relator counsel look at when considering these issues
• Recent enforcement actions involving private-equity-backed health care companies and discuss to what extent this is an area of focus for both the federal and state governments
• Due diligence and compliance integration strategies to mitigate the potential of post-closing false claims act risk
• The broader policy and ethical debates in health care and enforcement accountability
• How private equity investors can decrease potential false claims act risk

Expectations were high that the new administration would take a more business-friendly approach to antitrust enforcement, but the reality is more complex and more of a mixed bag. This panel of experienced private practitioners and a government enforcer will provide an update on the current landscape of federal, state, and private antitrust enforcement actions in key areas:

• Merger enforcement, including policy developments, the government’s current approach to remedies, changes in the HSR rules and compliance, and recent enforcement actions in the health care industry
• Non-merger enforcement, including policy developments and key enforcement areas of focus, such as labor markets, algorithmic pricing, information sharing, and payer-provider contracting
• Practical advice for health care organizations to navigate antitrust risks

• Dive into the hottest trends in health care AI—from regulatory sandboxes and agentic tools to patient-facing chatbots, clinical decision support, and AI-enabled operations
• Understand the fast-moving legal and regulatory landscape shaping AI in health care, including developments from FDA, HHS, The Joint Commission, and state legislatures
• Learn how leading health systems are building AI governance that works by aligning legal, compliance, clinical, privacy, security, and business teams
• Leave with strategies to be “hot without getting got”—adopting innovative AI tools in ways that are responsible, scalable, and regulator-ready

Join us for an interactive moderated panel on the continuously developing auditing and monitoring landscape for healthcare facilities. The panel will cover:

• Drawing “insight” from settlements to enhance “oversight” through auditing, monitoring, and creating a more adaptive, intelligence-driven compliance program
• Strategies for keeping pace with the constantly evolving federal and state regulations
• The evolving role of AI in auditing and monitoring–from acceptance to implementation
• Making lemonade from lemons–rethinking “imposed” compliance program requirements as a means to effectiveness
• What an auditing and monitoring program would look like if there were no budget constraints

Medicaid—the largest source of public coverage in the United States—will undergo its most consequential transformation since the Affordable Care Act as significant eligibility and financing statutory reforms take effect in the coming years. This session will discuss:

• A deep dive into the statutory and operational details of Medicaid's complex eligibility and financing framework
• Updates on H.R. 1 implementation, including up-to-the-minute rules and guidance from CMS and states about key eligibility, financing and other changes
• State implementation progress to date and impact to state budgets
• How entities across the healthcare ecosystem and their counsels are planning for these consequential changes

• How integration pushes the boundaries of privacy law, especially the interplay between HIPAA and 42 CFR Part 2 in multi-provider and tech-enabled care
• How the 2024 Parity Rule is reshaping compliance for payers and self-funded employers, with insights from litigation and DOL enforcement
• How OMB, CMS, and DOL oversight collectively drive behavioral health policy and integrated-care innovation
• Cross-state licensure and telehealth barriers, along with emerging compacts and payer/employer-driven solutions
• Reimbursement, contracting, and operational challenges of embedding behavioral health into primary care and value-based models
• How 988, digital behavioral health, and Medicaid demonstrations are influencing commercial and ERISA plan strategies, shared goals around regulatory clarity, and pathways for compliant integration across markets

• HIPAA Modernization and Potential Expansion: Proposed changes to HIPAA would include mandatory multi-factor authentication, encryption of ePHI, and annual technical evaluations to address evolving cybersecurity threats while a new bill, HIPRA, seeks to expand HIPAA-like requirements to non-PHI
• FTC Expands Oversight Beyond HIPAA: Health apps and connected devices must comply with the Health Breach Notification Rule; recent enforcement actions highlight risks for non-HIPAA entities
• State-Level Privacy Laws Gain Momentum: Washington’s My Health My Data Act and California’s CPRA impose strict consent, transparency, and geofencing restrictions, creating a complex compliance landscape
• Litigation and Emerging Risks: State laws introduce private rights of action, and recent court rulings on sensitive health data (e.g., reproductive health) signal ongoing regulatory uncertainty

• Popular payment incentives to promote physician, loyalty, such as signing bonuses, retention, bonuses, the shift towards payment for quality from productivity, value based bonuses, and early termination penalties
• Fraud and abuse risks and solutions under the federal antikickback law and the Stark law. This will include a discussion of the value-based enterprise exceptions and relevant OIG opinions
• Discuss at a high-level other legal implications, such as tax, contract and employment law implications

• What are the federal enforcement priorities and activities in this area including criminal enforcement, civil False Claims Act enforcement, off-label promotion under the Food Drug and Cosmetic Act and federal consumer protection laws? Have agencies moved to terminate Medicare/Medicaid participation or federal research or education funding for providers continuing to provide such care? Are enforcement efforts continuing against providers who have ceased providing such care?
• What state enforcement activities or private lawsuits are occurring in states that consider termination or limitation of such care to be a violation of their antidiscrimination laws?
• What is happening regarding the litigation challenging the two Executive Orders (EO 14168 and 14187) in this area?
• What is the current landscape on motions to quash DOJ subpoenas for patient records related to gender-affirming care including the QueerDoc appeal?
• What are the likely repercussions of recent HHS activity including the Dec. 18 2025 proposed rules on funding and conditions of participation and Kennedy Declaration, and referrals to HHS OIG?
• What compliance measures should providers be taking to reduce retrospective or current risk of civil or criminal liability in connection with providing gender-affirming care?

• Professional corporation tax entity type and accounting method
• Updates and variations in state corporate practice medicine of prohibitions
• How to structure a management services organization/professional corporation arrangement, from legal and tax perspectives
• Updates in restrictions on private equity investors and health care transaction notice and approval requirements
• Due diligence scrutiny and trends in telehealth due diligence–health care regulatory compliance and potential Federal and State tax exposure

This interactive session pairs an in-house hospital counsel with a physician-side transactional attorney for a candid “across the table” discussion of the following cutting-edge challenges shaping the 2026 regulatory environment and analysis of competing priorities (e.g., compliance versus autonomy, risk versus flexibility):

• Differing Perspectives: Addressing competing priorities and transaction operational challenges of health care delivery
• AI Diagnostic Partnerships: Counsel perspectives on intellectual property ownership, FDA oversight, bias mitigation, and malpractice exposure in co-developed decision-support tools.
• Hospital Acquisitions of Physician Groups: Navigating antitrust scrutiny, Stark and Anti-
• Kickback valuation standards, and deal dynamics amid continued uncertainty over noncompete enforcement
• ER Call Coverage and Reimbursement Pressures: Addressing fair market value, No Surprises Act implications, and burnout in negotiations between hospitals and physician groups

This session would take a deep dive into the legal implications of how prescription drugs are regulated, purchased, and reimbursed in the US. It will cover trends in 340B, commercial reimbursement, Medicare and Medicaid reimbursement, pharmacy benefit managers, Medicare and Medicaid rebates, the Drug Supply Chain Security Act, emerging direct to consumer models, TrumpRx, the Inflation Reduction Act, and/or other hot topics in drug pricing.

• The increase in government scrutiny and audits of hospice and home health agencies nationwide
• Updated disclosure and Medicare enrollment requirements
• The heightened federal and state inspections of hospice and home health providers
• The increase in hospice oversight activities and the results and implications for providers
• Strategic guidance to best position hospice and home health agencies to be successful in this challenging climate

Health care lawyers often stand at the intersection of organizational obligations and individual professional duties. These obligations and duties can collide when compliance concerns arise, or a government entity launches an investigation or serves a subpoena. This session will examine the ethical challenges that emerge when advising facilities, executives, and licensed providers who may themselves have independent reporting obligations or even be potential whistleblowers. In this session, we will address:

• Approaches for advising employees and physicians who may have personal reporting duties as licensed professions or may be potential whistleblowers
• Conflicts of interest that arise during internal investigations and strategies for navigating those conflicts
• Managing representation boundaries and ethical risks in response to government subpoenas and investigations
• Key professional responsibility principles that guide lawyers in these situations, including organizational representation, conflict of interest and interactions with unrepresented individuals

Cut through tax policy complexity and discover tactics and strategies to protect your hospital’s mission while staying financially strong. This session will provide a timely and strategic overview of how evolving tax laws are impacting tax-exempt hospitals. Our expert panel will guide attendees through key developments and offer practical approaches to help navigate a rapidly changing landscape. We will discuss:

• Recent developments–like renewed interest in joint-ventures and applying unrelated business income rule to emerging revenue-raising opportunities–to keep your hospital compliant and competitive
• Translate policy updates into actionable steps, from launching mission-aligned service lines to divesting underperforming business units
• Strengthen charity care and financial assistance programs by streamlining patient enrollment and equipping staff to prevent coverage lapses
• Calculate the true value of your tax exemption and leverage it as a strategic asset in community engagement
• Demystify executive compensation rules under IRC 4960, with tactics to navigate compliance requirements and understand market competitiveness

• How AI accreditation requirements translate into concrete legal and compliance tasks for AI procurement, deployment and implementation
• New issues and topics in contract language (SOWs, performance obligations, disclosures, audit rights) that impact AI governance and accreditation
• Governance expectations (leadership roles, quality program integration, documentation) to support defensible AI oversight
• Practices that enhance responsible adoption and deployment rates for AI tools, products and services in their organizations
• How to work with multi-disciplinary teams to stand-up and administer AI governance functions
• How organizations can bridge the gap between accreditation standards on paper and day-to-day operational governance–from AI-augmented case processing to audit-ready documentation

Through executive orders, new priorities, and policy changes, the second Trump administration has given DOJ a broad mandate for health care-related enforcement. This panel will feature a dynamic exchange among False Claims Act experts as they unpack the Administration’s key moves and assess the implications for health care providers and potential ways to respond. Topics will include:

• The changing enforcement landscape affecting the health care industry
• Key enforcement cases during the second Trump Administration
• Executive Orders impacting enforcement
• DOJ’s continued emphasis on leniency programs and whistleblowers
• How the Trump Administration is responding to the role of private equity in the health care industry
• Other emerging enforcement trends

• Popular payment incentives to promote physician, loyalty, such as signing bonuses, retention, bonuses, the shift towards payment for quality from productivity, value based bonuses, and early termination penalties
• Fraud and abuse risks and solutions under the federal antikickback law and the Stark law. This will include a discussion of the value-based enterprise exceptions and relevant OIG opinions
• Discuss at a high-level other legal implications, such as tax, contract and employment law implications

This panel will provide an essential legal roadmap for navigating the women's health regulatory environment, moving beyond traditional reproductive health discussions to address the full spectrum of challenges across three key pillars: access, research, and investment. We will discuss:

• Access to care in a post-Dobbs environment, including regulations governing reproductive health and health equity; service delivery methods; and risk mitigation strategies
• The legal and regulatory framework governing inclusion and representation in clinical trials; the impact of federal funding lapses on women's health research; and considerations on research design and subject recruitment.
• The growth of "FemTech" and regulatory, payment, and legal landscape they face

Expectations were high that the new administration would take a more business-friendly approach to antitrust enforcement, but the reality is more complex and more of a mixed bag. This panel of experienced private practitioners and a government enforcer will provide an update on the current landscape of federal, state, and private antitrust enforcement actions in key areas:

• Merger enforcement, including policy developments, the government’s current approach to remedies, changes in the HSR rules and compliance, and recent enforcement actions in the health care industry
• Non-merger enforcement, including policy developments and key enforcement areas of focus, such as labor markets, algorithmic pricing, information sharing, and payer-provider contracting
• Practical advice for health care organizations to navigate antitrust risks

• Dive into the hottest trends in health care AI—from regulatory sandboxes and agentic tools to patient-facing chatbots, clinical decision support, and AI-enabled operations
• Understand the fast-moving legal and regulatory landscape shaping AI in health care, including developments from FDA, HHS, The Joint Commission, and state legislatures
• Learn how leading health systems are building AI governance that works by aligning legal, compliance, clinical, privacy, security, and business teams
• Leave with strategies to be “hot without getting got”—adopting innovative AI tools in ways that are responsible, scalable, and regulator-ready

Medicaid—the largest source of public coverage in the United States—will undergo its most consequential transformation since the Affordable Care Act as significant eligibility and financing statutory reforms take effect in the coming years. This session will discuss:

• A deep dive into the statutory and operational details of Medicaid's complex eligibility and financing framework
• Updates on H.R. 1 implementation, including up-to-the-minute rules and guidance from CMS and states about key eligibility, financing and other changes
• State implementation progress to date and impact to state budgets
• How entities across the healthcare ecosystem and their counsels are planning for these consequential changes

• The current administration's spotlight on diversity, equity, and inclusion programs
• Potential government inquiries from DOJ, HHS OCR, State Attorney Generals, and other agencies
• Various federal funding streams that may leave your company vulnerable to federal investigations
• Past or pending government investigations into DEI programs
• Best practices to avoid government scrutiny and minimize harm from any past problematic conduct

• Stark Law issue trends, hot-button issues in Stark law financial arrangements based on SRDP submissions, frequent questions, and what’s likely on the horizon
• Review and analyze through hypothetical scenarios
• Value-based arrangements, risks and rewards, and their ability to shape financial relationships with physicians
• Hear latest from CMS officials

• Breaking down the OIG Compliance Guidance for Medicare Advantage Industry Segment
• Hot issues: RADV, AI, and prior authorizations
• What’s new for plans
• Operational impacts for providers
• Practical tips for aligning compliance programs with the new expectations

• Legal framework for use of variable compensation and earnouts in healthcare transactions (Stark, state and federal anti-kickback laws, EKRA, state fee splitting laws, etc.)
• Tools to evaluate variable compensation methodologies and earnouts, including an “Earnout Decision Tree” that participants can utilize in their practices
• Best practices for structuring variable compensation to reduce risk and strategies for designing compliant approaches that promote business goals but do not rely on inducing referrals
• Hypothetical fact scenarios to illustrate risk spectrum and note where they have received guidance from case law, DOJ enforcement, or discussions with government investigators

• How to prepare for ICE raids in worksites with sensitive information, patients, and employee populations
• Addressing Worksite compliance requirements in a new era of heightened enforcement (e.g. new requirements for forms I-9)
• Update on immigration staffing options for healthcare occupations: How the TN and H-1B rule changes affect health care employers
• Immigration staffing options: The rise in foreign nurse visas within the US (A roadmap for staffing nurses and other occupations in a changing immigration climate)

Learn from Mike Pazzo, Chief Legal Officer of Roper St. Francis Healthcare, and Mark Despoth, Internal Audit Director, how to implement an innovative approach to proactively addressing physician arrangement regulatory risk. Participants will learn:

• How you can partner with Internal Audit to perform pre-payment audits of your physician arrangements (compensation, real estate, etc)
• How you can develop a corporate-program to audit your arrangements and lower your regulatory risk profile
• How to address regulatory risks before they become a problem through pre-payment audits
• To develop robust reporting from your pre-payment reviews so that operational leaders can learn from and reinforce with those submitting and reviewing payment requests
• How to realize cost-savings and reduce the risk of costly regulatory nightmares

• HIPAA Modernization and Potential Expansion: Proposed changes to HIPAA would include mandatory multi-factor authentication, encryption of ePHI, and annual technical evaluations to address evolving cybersecurity threats while a new bill, HIPRA, seeks to expand HIPAA-like requirements to non-PHI
• FTC Expands Oversight Beyond HIPAA: Health apps and connected devices must comply with the Health Breach Notification Rule; recent enforcement actions highlight risks for non-HIPAA entities
• State-Level Privacy Laws Gain Momentum: Washington’s My Health My Data Act and California’s CPRA impose strict consent, transparency, and geofencing restrictions, creating a complex compliance landscape
• Litigation and Emerging Risks: State laws introduce private rights of action, and recent court rulings on sensitive health data (e.g., reproductive health) signal ongoing regulatory uncertainty

The latest on continuing implementation of No Surprises Act (NSA) provisions, including:

• Progress towards an Advanced Explanation of Benefits
• Lingering questions re: Good Faith Estimates
• Qualifying Payment Amount calculations
• Current state of play re: Independent Dispute Resolution (IDR) and challenges to IDR awards
• Continuing NSA-related litigation
• Other NSA issues, disputes and complaints–and how to handle them

This session will discuss ways in which participants can handle various provider professionalism (behavior/conduct) issues, including benefits and drawbacks of handling through the Medical Staff or HR/employment process

• Professionalism concerns–should these be handled separately from quality and safety concerns?
  • At what point do professionalism concerns become quality/safety concerns
• How the processes can work at the same time, sharing information with HR, and sharing information with external employers
• How issues would proceed through the Medical Staff and HR processes. Discussion regarding issues with each process
  • What actions may be taken when the Medical Staff does not like HR determination; is there a time limit on taking action through peer review processes
  • What impact would a HR PIP or similar have on Medical Staff peer review

This interactive session pairs an in-house hospital counsel with a physician-side transactional attorney for a candid “across the table” discussion of the following cutting-edge challenges shaping the 2026 regulatory environment and analysis of competing priorities (e.g., compliance versus autonomy, risk versus flexibility):

• Differing Perspectives: Addressing competing priorities and transaction operational challenges of health care delivery
• AI Diagnostic Partnerships: Counsel perspectives on intellectual property ownership, FDA oversight, bias mitigation, and malpractice exposure in co-developed decision-support tools.
• Hospital Acquisitions of Physician Groups: Navigating antitrust scrutiny, Stark and Anti-
• Kickback valuation standards, and deal dynamics amid continued uncertainty over noncompete enforcement
• ER Call Coverage and Reimbursement Pressures: Addressing fair market value, No Surprises Act implications, and burnout in negotiations between hospitals and physician groups

This session would take a deep dive into the legal implications of how prescription drugs are regulated, purchased, and reimbursed in the US. It will cover trends in 340B, commercial reimbursement, Medicare and Medicaid reimbursement, pharmacy benefit managers, Medicare and Medicaid rebates, the Drug Supply Chain Security Act, emerging direct to consumer models, TrumpRx, the Inflation Reduction Act, and/or other hot topics in drug pricing.

Cut through tax policy complexity and discover tactics and strategies to protect your hospital’s mission while staying financially strong. This session will provide a timely and strategic overview of how evolving tax laws are impacting tax-exempt hospitals. Our expert panel will guide attendees through key developments and offer practical approaches to help navigate a rapidly changing landscape. We will discuss:

• Recent developments–like renewed interest in joint-ventures and applying unrelated business income rule to emerging revenue-raising opportunities–to keep your hospital compliant and competitive
• Translate policy updates into actionable steps, from launching mission-aligned service lines to divesting underperforming business units
• Strengthen charity care and financial assistance programs by streamlining patient enrollment and equipping staff to prevent coverage lapses
• Calculate the true value of your tax exemption and leverage it as a strategic asset in community engagement
• Demystify executive compensation rules under IRC 4960, with tactics to navigate compliance requirements and understand market competitiveness

The interactive panel will cover the evolving landscape of health care antitrust with practical insights and takeaways. The panel will cover:

• Current regulatory and enforcement landscape + scrutiny at both federal- and state-level with respect to health care transactions, horizontal and vertical integration and more
• Strategies among the shifts in the health care transactions landscape, and the government’s evolving approach to enforcement
• Practical considerations and best practices to manage antitrust issues and impact on potential transactions

This session will explore the intersection of private equity investment, health care regulatory frameworks, and state and federal false claims act exposure. The presenters will discuss the theories seeking to implicate investors for portfolio company misconduct, analyze the evolving enforcement posture, and provide practical guidance for managing compliance risk. We will discuss:

• How private equity ownership structures can intersect with state and federal false claims acts and fraud-and-abuse laws
• Potential red flags in investment transactions and operations that could expose investors or portfolio companies to state and federal false claims act liability and areas that government and relator counsel look at when considering these issues
• Recent enforcement actions involving private-equity-backed health care companies and discuss to what extent this is an area of focus for both the federal and state governments
• Due diligence and compliance integration strategies to mitigate the potential of post-closing false claims act risk
• The broader policy and ethical debates in health care and enforcement accountability
• How private equity investors can decrease potential false claims act risk

Join us for an interactive moderated panel on the continuously developing auditing and monitoring landscape for healthcare facilities. The panel will cover:

• Drawing “insight” from settlements to enhance “oversight” through auditing, monitoring, and creating a more adaptive, intelligence-driven compliance program
• Strategies for keeping pace with the constantly evolving federal and state regulations
• The evolving role of AI in auditing and monitoring–from acceptance to implementation
• Making lemonade from lemons–rethinking “imposed” compliance program requirements as a means to effectiveness
• What an auditing and monitoring program would look like if there were no budget constraints

• How AI accreditation requirements translate into concrete legal and compliance tasks for AI procurement, deployment and implementation
• New issues and topics in contract language (SOWs, performance obligations, disclosures, audit rights) that impact AI governance and accreditation
• Governance expectations (leadership roles, quality program integration, documentation) to support defensible AI oversight
• Practices that enhance responsible adoption and deployment rates for AI tools, products and services in their organizations
• How to work with multi-disciplinary teams to stand-up and administer AI governance functions
• How organizations can bridge the gap between accreditation standards on paper and day-to-day operational governance–from AI-augmented case processing to audit-ready documentation

• Stark Law issue trends, hot-button issues in Stark law financial arrangements based on SRDP submissions, frequent questions, and what’s likely on the horizon
• Review and analyze through hypothetical scenarios
• Value-based arrangements, risks and rewards, and their ability to shape financial relationships with physicians
• Hear latest from CMS officials

Learn from Mike Pazzo, Chief Legal Officer of Roper St. Francis Healthcare, and Mark Despoth, Internal Audit Director, how to implement an innovative approach to proactively addressing physician arrangement regulatory risk. Participants will learn:

• How you can partner with Internal Audit to perform pre-payment audits of your physician arrangements (compensation, real estate, etc)
• How you can develop a corporate-program to audit your arrangements and lower your regulatory risk profile
• How to address regulatory risks before they become a problem through pre-payment audits
• To develop robust reporting from your pre-payment reviews so that operational leaders can learn from and reinforce with those submitting and reviewing payment requests
• How to realize cost-savings and reduce the risk of costly regulatory nightmares